Gritstone Oncology Company
Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. Gritstone Oncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS.
Investors
Founded Date:
2015-08-01
Total Funding:
476000000.0
Employee Number:
101-250
Funding Status:
IPO
Technology:
Biotechnology, Health Care, Therapeutics
Last Funding Type:
Post-IPO Equity
Investors Number:
16.0
Last Funding Date:
2022-07-22
Industry:
Preclinical Development
Headquarters:
Emeryville, California, United States
Estimated Revenue:
$1M to $10M